Zafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors Read more about Zafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions® Read more about Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions® Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society Read more about Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity Read more about Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer Read more about Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer Zafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association’s 73rd Scientific Sessions® Read more about Zafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association’s 73rd Scientific Sessions® Zafgen Secures $45 Million in Series E Financing Read more about Zafgen Secures $45 Million in Series E Financing Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors Read more about Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome Read more about Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome Zafgen Announces Support of NORD in Observing Rare Disease Day Read more about Zafgen Announces Support of NORD in Observing Rare Disease Day Pagination First page « First Previous page ‹ Previous … Page 17 Page 18 Page 19 Page 20 Page 21 Page 22 Page 23 Current page 24 Page 25 Next page Next › Last page Last » Subscribe to
Zafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors Read more about Zafgen Appoints Business Development Veteran Frances K. Heller to Board of Directors
Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions® Read more about Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1 Studies of Beloranib in Obesity at American Diabetes Association’s 72nd Scientific Sessions®
Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society Read more about Zafgen Announces Additional Weight Loss and Cardiometabolic Data from Phase 1b Studies of Beloranib in Obesity at Obesity 2012, the 30th Annual Scientific Meeting of The Obesity Society
Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity Read more about Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer Read more about Zafgen Appoints 20-Year Biotechnology Industry Veteran Patricia Allen, CPA, as Chief Financial Officer
Zafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association’s 73rd Scientific Sessions® Read more about Zafgen Announces New Body Weight Loss and Cardiometabolic Data from Phase 2 Study of Beloranib in Obesity at American Diabetes Association’s 73rd Scientific Sessions®
Zafgen Secures $45 Million in Series E Financing Read more about Zafgen Secures $45 Million in Series E Financing
Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors Read more about Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome Read more about Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Zafgen Announces Support of NORD in Observing Rare Disease Day Read more about Zafgen Announces Support of NORD in Observing Rare Disease Day